 While third quarter results were not really great, Gilead Sciences could beat expectations, raised its guidance, and grew at a solid pace when excluding Veklury. Especially Biktarvy, Trodelvy, Yescarta, and Sunlenca will contribute to growth in the years to come, while the risk of declining revenue from patent loss is rather low in the next. 